Request Demo
Last update 30 May 2025
Irradiated Allogeneic Cells(NCI)
Last update 30 May 2025
Overview
Basic Info
Drug Type Cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedEarly Phase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Irradiated Allogeneic Cells(NCI)NCT03272633
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
100 Clinical Results associated with Irradiated Allogeneic Cells(NCI)
Login to view more data
100 Translational Medicine associated with Irradiated Allogeneic Cells(NCI)
Login to view more data
100 Patents (Medical) associated with Irradiated Allogeneic Cells(NCI)
Login to view more data
100 Deals associated with Irradiated Allogeneic Cells(NCI)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Phase 1 | United States | 26 Oct 2020 | |
| Acute Myeloid Leukemia | Phase 1 | United States | 26 Oct 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 1 | United States | 26 Oct 2020 | |
| Diffuse large B-cell lymphoma refractory | Phase 1 | United States | 26 Oct 2020 | |
| Hematopoietic stem cell transplantation | Phase 1 | United States | 26 Oct 2020 | |
| Mantle-Cell Lymphoma | Phase 1 | United States | 26 Oct 2020 | |
| Multiple Myeloma | Phase 1 | United States | 26 Oct 2020 | |
| Myelodysplastic Syndromes | Phase 1 | United States | 26 Oct 2020 | |
| Relapsing acute myeloid leukemia | Phase 1 | United States | 26 Oct 2020 | |
| Residual Neoplasm | Phase 1 | United States | 26 Oct 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Early Phase 1 | 2 | Allogeneic Hematopoietic Stem Cell Transplantation+Irradiated Allogeneic Cells (Cohort I (Initial IHC Within 42 Days)) | qwhxhhegee(yzagnmzckm) = isexjwzftn feflfuzipe (obswnacpld, pzewupluee - sgznxlhkmt) View more | - | 26 Jun 2023 | ||
Allogeneic Hematopoietic Stem Cell Transplantation+Irradiated Allogeneic Cells (Cohort II (Initial IHC Within 70 Days or After Relapse)) | hygodpcyqu = ccwsnxcnhl toxdvnereb (zzcpnfpxjg, nfzqayxfxv - dqnryzqwqj) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free